• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

81.93 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 161
Open 81.93
Bid (Size) 76.25 (200)
Ask (Size) 99.00 (100)
Prev. Close 81.93
Today's Range 81.93 - 81.93
52wk Range 28.66 - 126.38
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CORT Q3 2026 deep dive: rapid Lifyorli uptake and pipeline expansion shape outlook
Today 0:39 EST
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 64% year on year to $... 
Via StockStory
News headline image
Corcept Therapeutics Q3 Earnings Call Highlights ↗
November 03, 2026
Corcept Therapeutics (NASDAQ:CORT) reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the... 
Via MarketBeat
Topics Earnings

Performance

52-Week Range 35.2% below 52-week high
81.93
28.6652W Low 126.3852W High
1 Week 7.5% below 1-week high
79.391W Low 88.591W High

Corcept Therapeutics Incorporated - Common Stock (CORT) traded between $28.66 and $126.38 over the past 52 weeks and last traded at $81.93, 35.2% below its 52-week high. Over the past week it ranged between $79.39 and $88.59.

Past 12 Months
-5.0%
-32.9%
-25.4%
+59.6%
+114.5%
+10.5%
1W -$4.35
1M -$40.10
3M -$27.87
6M +$30.60
YTD +$43.73
1Y +$7.76

CORT was +10.5% over the past year, +59.6% over six months, +114.5% year to date, -5.0% in the last week.

12 Months vs Market
CORT
+10.5%
DIA
+9.2%
SPY
+10.4%
QQQ
+8.4%
IWM
+14.0%

Over the past 12 months CORT returned +10.5% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 0.00× 3-mo avg
Today 161 3-mo avg 1.2M
1W
1.4M
1M
989.0K
3M
1.2M
6M
1.2M
YTD
1.5M
1Y
1.5M

CORT most recently traded 161 shares against a 3-month average daily volume of 1.2M.

More News

Read More
Corcept Therapeutics (NASDAQ:CORT) Q3 EPS Beat Offset by In-Line Revenue and Reiterated Guidance ↗
November 03, 2026
Via Chartmill
News headline image
Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue
November 03, 2026
Via StockStory
Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup ↗
September 17, 2026
Via Chartmill
News headline image
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
November 03, 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept (CORT) to report earnings tomorrow: here is what to expect
November 01, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 27, 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
October 26, 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks
October 25, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks
October 22, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
2 cash-producing stocks to research further and 1 we find risky
October 22, 2026
Via StockStory
Topics Energy
News headline image
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
October 20, 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 Cash-Heavy Stock to Keep an Eye On and 2 We Question
October 15, 2026
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers
October 12, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Sell CORT and 1 Stock to Buy Instead
October 06, 2026
Via StockStory
News headline image
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
September 28, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Corcept Announces Planned Leadership Transition
September 23, 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Branded Pharmaceuticals Stocks Q2 In Review: Phibro Animal Health (NASDAQ:PAHC) Vs Peers
September 22, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 of Wall Street’s Favorite Stocks We Keep Off Our Radar
September 22, 2026
Via StockStory
News headline image
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
September 18, 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
2 Healthcare Stocks to Research Further and 1 We Find Risky
September 16, 2026
Via StockStory
News headline image
1 Growth Stock Set to Flourishand 2 We Brush Off
September 01, 2026
Via StockStory
Topics Supply Chain
News headline image
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
August 31, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
August 24, 2026
Via StockStory
Topics Artificial Intelligence Intellectual Property

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 81.93
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 11/03/26 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 9.50B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap